Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor cell membrane proteins that serve as ligands for activating receptors on natural killer (NK) cells. These proteins, often upregulated or expressed de novo on tumor cells due to stress or transformation, play a crucial role in triggering NK cell-mediated cytotoxicity and tumor surveillance. Key examples include MICA/B, ULBPs, B7-H6, PCNA, and CD112/CD155. Engagement of these ligands by activating receptors such as NKG2D, NKp30, NCRs and DNAM-1 promotes NK cell activation and subsequent tumor cell lysis.
Engagement of NK cell activating receptors leads to degranulation, release of perforin/granzymes, induction of apoptosis, and cytokine secretion (IFNγ, TNFα), resulting in tumor cell lysis or inhibition of survival signals.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Cell Membrane Proteins Recognized by Activating Receptors on Natural Killer (NK) Cells (NK Cell Activating Ligands).